Alta Sciences

AUGUST 29, 2024

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD by 2028. billion USD in 2023 to $166.53 WHAT IS THE ALTASCIENTIST

Drug Development 52

Drug Development Small Molecule Clinical Trials Drugs 52

Alta Sciences

APRIL 5, 2024

The mini documentary explores transformation in the slow-to-change drug development industry. Leaders from Altasciences dive into the obstacles and inefficiencies of the traditional outsourcing relationship between CROs and drug sponsors, and how Altasciences has broken from tradition to address these challenges.

Drug Development 52

Drug Development Pharma Companies Marketing Drugs 52

DrugBank

AUGUST 9, 2024

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.    The average cost of bringing a new drug to market is about $2.6 trillion by 2028.

Pharmaceuticals 76

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 76

Agency IQ

AUGUST 16, 2024

By Amanda Conti | Aug 13, 2024 10:00 PM CDT Regulatory context: Psychedelic regulation and drug development A growing body of evidence suggests that psychedelics may provide clinical benefit for certain purposes, especially mental health conditions. The road to research on psychedelic products is paved with obstacles.

FDA 40

FDA Trials Therapies Regulations 40

Codon

SEPTEMBER 29, 2024

The lab created a plan with eight research institutions across three continents. 2028 Over the next year, the scientific community ferociously interrogated the model. It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. However, no such dataset existed.

Engineering 126

Engineering Virus DNA Therapies 126

Agency IQ

FEBRUARY 2, 2024

In some less common cases, a test or diagnostic may be technically classified as a biological product and regulated under the Center for Biologics Evaluation and Research (CBER) (e.g., A sea change for lab tests, the implications for drug developers and outstanding questions about endpoints In the U.S., In the U.S.,

FDA 40

FDA Laboratories Regulations Production 40